Search

Your search keyword '"Fustier, P."' showing total 23 results

Search Constraints

Start Over You searched for: Author "Fustier, P." Remove constraint Author: "Fustier, P." Database Unpaywall Remove constraint Database: Unpaywall
23 results on '"Fustier, P."'

Search Results

1. Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial

4. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

5. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

6. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

7. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)

8. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO

9. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Catalog

Books, media, physical & digital resources